Lupin shares edged higher in early trading after the pharma company, on Wednesday, received approval from the United States Food and Drug Administration (USFDA) for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 ml, to market a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc. The shares of Lupin touched an intra-day high of Rs 1,025, up 2.4 per cent in early trading, and at 10:25 am, the shares were trading at Rs 101.30, up 0.35 per cent on the BSE.
Sulfamethoxazole and Trimethoprim Oral Suspension USP is indicated for treating and preventing a variety of bacterial infections, such as middle ear, urine, respiratory, and intestinal infections, and certain type of pneumonia such as pneumocystis, Lupin said in a regulatory filing to the stock exchanges.
Sulfamethoxazole and Trimethoprim Oral Suspension USP had estimated annual sales of approximately USD 19 million in the United States, the pharma company added.
The BSE Sensex was trading at Rs 48,321.72, higher by 141.69 points or 0.29 per cent and NSE Nifty was at 14,194.55, up 49.85 points or 0.35 per cent at the time.